Home » Takeda’s Hypertension Treatment Enters Phase II Clinical Stage
Takeda’s Hypertension Treatment Enters Phase II Clinical Stage
Takeda Pharmaceutical announced that its investigational compound, TAK-536, has entered into Phase II clinical trials in Japan.
According to Tekeda, TAK-536 is an angiotensin receptor blocker (ARB) whose mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.
The company added that it expects TAK-536 to show stronger antihypertensive action, and also to have superior profile in improving the insulin resistance and renal protective action when compared with existing ARBs.
Upcoming Events
-
07May
-
14May
-
30May